Zobrazeno 1 - 10
of 362
pro vyhledávání: '"psoriasi"'
Autor:
Giacomo Caldarola, A Chiricozzi, M Megna, P Dapavo, A Giunta, M Burlando, P Malagoli, V Dini, M Mariani, G Fabbrocini, P Quaglino, L Bianchi, A Parodi, K Peris, C De Simone
Publikováno v:
Expert Opinion on Biological Therapy. 23:365-370
Background: Confirmatory data on long-term effectiveness and safety of ixekizumb in psoriatic patients from real-world studies are needed. Objectives: The primary aim was to evaluate the 3-year drug survival of ixekizumab in the treatment of patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c5d2a3d17c932e8dd4bafd199e7017e
https://doi.org/10.1080/14712598.2023.2193288
https://doi.org/10.1080/14712598.2023.2193288
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Angelo Ruggiero, Gabriella Fabbrocicni, Sara Cacciapuoti, Luca Potestio, Lucia Gallo, Matteo Megna
Publikováno v:
Clinical, Cosmetic and Investigational Dermatology. 16:529-536
Angelo Ruggiero, Gabriella Fabbrocicni, Sara Cacciapuoti, Luca Potestio, Lucia Gallo, Matteo Megna Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyCorrespondence: Angelo Ruggiero, Se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e900d3ee1cf543e3b8158b166fc3ed3
https://doi.org/10.2147/ccid.s402183
https://doi.org/10.2147/ccid.s402183
Autor:
Vasiliki A. Nikolaou, Zoe Apalla, Cristina Carrera, Davide Fattore, Pietro Sollena, Julia Riganti, Sonia Segura, Azael Freites-Martinez, Konstantinos Lallas, Maria Concetta Romano, Chrysa Oikonomou, Michela Starace, Meletios A. Dimopoulos, Athanassios Kyrgidis, Elizabeth Lazaridou, Priscila Giavedoni, Maria Carmela Annunziata, Ketty Peris, Maria Echeverría, Emilio Lopez-Tujillo, Konstandinos Syrigos, Chryssoula Papageorgiou, Sebastian Podlipnik, Gabriella Fabbrocini, Ana C. Torre, Christina Kemanetzi, Lorena Villa-Crespo, Aimilios Lallas, Alexander J. Stratigos, Vincent Sibaud
Publikováno v:
British Journal of Dermatology. 187:962-969
Summary Background Cutaneous immune-related adverse events (irAEs) represent the most frequent toxicities induced by immune checkpoint inhibitors (ICIs). Objectives To investigate clinical associations of cutaneous toxicities induced by different ICI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c4aadd646c88daacde9b8116850e384
https://doi.org/10.1111/bjd.21781
https://doi.org/10.1111/bjd.21781
Autor:
Francesco Bellinato, Paolo Gisondi, Angelo Valerio Marzano, Stefano Piaserico, Clara De Simone, Giovanni Damiani, Giuseppe Argenziano, Marina Venturini, Paolo Dapavo, Antonio Costanzo, Matteo Megna, Francesca Prignano, Martina Burlando, Francesca Satolli, Andrea Carugno, Elena Pezzolo, Marco Romanelli, Aldo Cuccia, Giampiero Girolomoni
Publikováno v:
Vaccines; Volume 11; Issue 4; Pages: 740
Background: Generalized pustular psoriasis (GPP) is a rare, severe inflammatory skin disease characterized by recurrent episodes of flares. Characteristics of patients experiencing a flare are hardly described in a real-life setting. The aim of the s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25b80a6e7193e88ccaa429ae23f797eb
Publikováno v:
Clinical, Cosmetic and Investigational Dermatology. 15:1649-1658
Interleukin (IL)-23 inhibitors, guselkumab, risankizumab, and tildrakizumab, represent the latest class of biologics approved for the treatment of moderate-to-severe psoriasis. Since their approval numerous real-life studies were published on anti-IL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea04c595551c3225ae439d5b1ed1b78d
https://doi.org/10.2147/ccid.s364640
https://doi.org/10.2147/ccid.s364640
Autor:
Rocco Spagnuolo, Francesco Salvatore Iaquinta, Daniele Mauro, Ilenia Pantano, Stefano Dastoli, Saverio Naty, Cristina Cosco, Rosellina Margherita Mancina, Daniela Iacono, Emanuela Gaggiano, Annarita Ruggiero, Steven Paul Nisticò, Francesco Ciccia, Rosa Daniela Grembiale, Doldo Patrizia
Publikováno v:
Reviews on Recent Clinical Trials. 17:177-186
Background: Although mood disorders have been well characterized by immune-mediated inflammatory diseases, physical function and satisfaction with social roles have not yet been defined as independent domains. Objective: The study aims to assess sati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::582b2e195bd1d61de4d8010ea62666b2
https://doi.org/10.2174/1574887117666220531162104
https://doi.org/10.2174/1574887117666220531162104
Autor:
Matteo Megna, Luigi Fornaro, Luca Potestio, Maria Antonietta Luciano, Mariateresa Nocerino, Mario Delfino, Maria Guarino, Gabriella Fabbrocini, Elisa Camela
Publikováno v:
Psoriasis: Targets and Therapy. 12:199-204
Matteo Megna, Luigi Fornaro, Luca Potestio, Maria Antonietta Luciano, Mariateresa Nocerino, Mario Delfino, Maria Guarino, Gabriella Fabbrocini, Elisa Camela Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Fe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f40f4c513da6ca60f6667a1d429d92da
https://doi.org/10.2147/ptt.s365493
https://doi.org/10.2147/ptt.s365493
Publikováno v:
Expert Opinion on Biological Therapy. 22:1503-1520
Introduction: Psoriasis prevalence in the elderly is growing. It is estimated that 15% of elderly psoriasis patients suffer from moderate-to-severe disease, thus requiring systemic treatments. However, conventional systemic agents' use is limited due
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98f184f87509c50bc62aaa593c5b2e40
https://doi.org/10.1080/14712598.2022.2089020
https://doi.org/10.1080/14712598.2022.2089020
Publikováno v:
Psoriasis: Targets and Therapy. 12:127-137
Bimekizumab, a novel humanized monoclonal IgG1 antibody that neutralizes both IL-17A and IL-17F, was recently approved the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Bimekizumab represents the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b417dc47b4dde487893d80d98dd1f383
https://doi.org/10.2147/ptt.s367744
https://doi.org/10.2147/ptt.s367744